



Received on 18 February 2021; received in revised form, 03 April 2021; accepted, 23 April 2021; published 01 May 2021

## PROTECTIVE EFFECT OF D-PINITOL ISOLATED FROM AERIAL PARTS OF SOYBEAN PLANTS ON HAEMATOLOGICAL PROFILE AGAINST DOXORUBICIN-INDUCED CYTOTOXICITY IN MICE

Murugesan Sudha <sup>\*1</sup> and Thangarasu Vetrichelvan <sup>2</sup>

Department of Pharmacology <sup>1</sup>, Department of Pharmaceutical Analysis <sup>2</sup>, Adhiparasakthi College of Pharmacy, Melmaruvathur - 603319, Tamil Nadu, India.

### Keywords:

D-Pinitol, Doxorubicin,  
Haematological parameters,  
Antioxidant effect, Free radical  
scavenging activity

### Correspondence to Author: Murugesan Sudha

M. Pharm., Ph.D,  
Assistant Professor,  
Department of Pharmacology,  
Adhiparasakthi College of Pharmacy,  
Cheyyur Taluk, Kancheepuram  
District, Kesavarayanpettai,  
Melmaruvathur - 603319, Tamil  
Nadu, India.

**E-mail:** kaviyasudha7@gmail.com

**ABSTRACT:** The aim of this research was to examine the protective effect of D-Pinitol on haematological profile against Doxorubicin-induced cytotoxicity in mice. Doxorubicin is a chemotherapeutic agent valuable in treating various cancers regardless of its toxicity to normal cells, including hematopoietic suppression. Oxidative stress and generation of reactive oxygen species appear to be the reason for Doxorubicin-induced cytotoxicity in bone marrow cells. D-Pinitol is a richly available carbohydrate in Soybean plants and it has been shown to possess free radical scavenging activity and antioxidant effect in previous researches. Sixty Swiss Albino mice were divided into ten groups: Control, Doxorubicin (5 mg/kg), D-Pinitol (100 mg/kg, 200 mg/kg, 300 mg/kg and 400 mg/kg) and D-Pinitol (100 mg/kg, 200 mg/kg, 300 mg/kg and 400 mg/kg) + Doxorubicin (5 mg/kg). Blood samples were taken from the mice to determine the blood levels of haematological parameters such as white blood cells, lymphocytes, monocytes, red blood cells, hemoglobin, hematocrit and platelets. The D-Pinitol-only treated groups reported no significant variations in haematological parameters compared to the control group. The blood levels of haematological parameters were decreased significantly in Doxorubicin alone treated group compared to the control group. In the Doxorubicin and D-Pinitol co-treated groups, D-Pinitol significantly elevated the blood levels of haematological parameters in a dose-dependent manner compared to the Doxorubicin group. Our findings suggested that the D-Pinitol co-treatment with Doxorubicin could effectively alleviate the accompanying Doxorubicin-induced cytotoxicity in bone marrow cells by attenuating oxidative stress and reactive oxygen species production through its antioxidant effect and free radical scavenging activity.

**INTRODUCTION:** Doxorubicin (DOX) is widely accepted as a potent broad-spectrum chemotherapeutic agent against different types of tumors. Its medicinal use was restricted because of its potential toxicities, including myelosuppression and cardiac toxicity <sup>1,2</sup>.

In bone marrow (hematopoietic) cells, the subsequent generation of reactive oxygen species (ROS) and the deterioration of endogenous antioxidants due to DOX administration can activate the intrinsic apoptotic pathway.

Oxidative stress also tends to play a major role in DOX-induced cytotoxicity in bone marrow cells. Harmful effects of DOX produced due to ROS production and oxidative stress could be alleviated with the usage of antioxidants and free radical scavengers. Antioxidants and free radical scavengers may protect hematopoietic cells by directly inactivating ROS or regulating ROS

<p><b>QUICK RESPONSE CODE</b></p>	<p><b>DOI:</b> 10.13040/IJPSR.0975-8232.12(5).2926-32</p> <hr/> <p>This article can be accessed online on <a href="http://www.ijpsr.com">www.ijpsr.com</a></p>
<p>DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.12(5).2926-32">http://dx.doi.org/10.13040/IJPSR.0975-8232.12(5).2926-32</a></p>	

signaling involved in genetic expression and attenuating oxidative stress<sup>1,3</sup>. Hence the treatment of cancer patients can be improved by a novel therapeutic strategy in which one compound having an antioxidant effect and free radical scavenging activity is used to improve DOX's antitumor efficacy while minimizing severe side effects<sup>1,4</sup>. D-Pinitol is present as a primary carbohydrate in *Glycine max* L. Merr (Soybean) plants<sup>5,6</sup>.

It creates tremendous interest in the worldwide scientific community because of its documented therapeutic benefits such as anti-neoplastic<sup>7</sup>, anti-inflammatory<sup>8</sup>, anti-diabetic<sup>9</sup>, hepatoprotective<sup>10</sup>, renal protective<sup>11</sup>, immuno-modulatory, preventive of osteoporosis<sup>5</sup> and Alzheimer's disease ameliorative<sup>12</sup>, etc.

Earlier literature indicated that D-Pinitol is efficient in scavenging free radicals and has antioxidant properties<sup>13, 14</sup>. Nevertheless, its role in the alleviation of complications associated with DOX chemotherapy is not studied.

Since, previous studies indicated that concomitant administration of antioxidant and free radicals scavenger with DOX could reduce the side effects of DOX<sup>15, 16</sup>, this study was intended to determine the impact of D-Pinitol on reducing the cytotoxic effect of DOX in bone marrow cells. An Automated hematology analyzer has been used in our study since it has been widely used as an easy, fast and reliable diagnostic method for humans and animals<sup>17</sup>.

## MATERIALS AND METHODS:

**Ethics Statement:** The experimental protocol was approved by Institutional Animal Ethics Committee (IAEC), Adhiparasakthi College of Pharmacy (Reg. No. 409/PO/Re/S/01/CPCSEA), and the approval number was APCP/IAEC/2019-2020/1.

**Statistical Analysis:** Statistical analysis was performed by one way ANOVA method. Values were expressed as mean and for n = 6. All data were analyzed with the GraphPad Prism 8.0.1 software. P < 0.05 was considered statistically significant.

**Materials Required:** Doxorubicin HCL (TCI chemicals, India), D-Pinitol isolated from aerial parts of Soybean (*Glycine max* L. Merr.,) plants, Mindray BC-3000 Auto Hematology Analyzer (Mindray Medical India Private Limited, India), Diluting fluid (CELLPACK DCL, Sysmex, India).

**Methodology:** Swiss Albino Mice (Sex: Male and Female; Weight: 25–30 g) were housed in cages and were kept on a 12 h light/dark cycle. Before the commencement of the study, the animals were acclimatized in cages maintained in a clean and controlled environment based on CPCSEA guidelines<sup>18</sup>.

**Treatment:** Ten groups of animals, each comprised of six mice, were taken for the study. Animals were treated with D-Pinitol for fifteen consecutive days and Doxorubicin for three days (on 1<sup>st</sup> day, 8<sup>th</sup> day and 15<sup>th</sup> day)<sup>21</sup> as per the treatment protocol. Haematological parameters (white blood cells, lymphocytes, monocytes, red blood cells, hemoglobin, hematocrit and platelets) were analysed before the treatment (day 1) and following the treatment (day 15) in an Automated Hematology Analyzer. 20 µl of blood sample was taken from the tail vein of each mouse by making a slight incision in the tail with the scalpel blade. Then blood was poured into an EDTA coated tube and was mixed gently. Then, 500 µl of diluents was added to the 20 µl of well-mixed whole blood sample. The blood was thoroughly mixed with diluting fluid using a pipette.

**TABLE 1: TREATMENT PROTOCOL**

Groups	Treatment
I	0.5 ml of 0.9% normal saline daily (Vehicle Control)
II	Doxorubicin (5 mg/kg), i.p. on 1 <sup>st</sup> , 8 <sup>th</sup> and 15 <sup>th</sup> days (Positive Control)
III	D-Pinitol (100 mg/kg), p.o. daily
IV	D-Pinitol (200 mg/kg), p.o. daily
V	D-Pinitol (300 mg/kg), p.o. daily
VI	D-Pinitol (400 mg/kg), p.o. daily
VII	Doxorubicin (5 mg/kg), i.p. on 1 <sup>st</sup> , 8 <sup>th</sup> and 15 <sup>th</sup> days +D-Pinitol (100 mg/kg), p.o. daily
VIII	Doxorubicin (5 mg/kg), i.p. on 1 <sup>st</sup> , 8 <sup>th</sup> and 15 <sup>th</sup> days +D-Pinitol (200 mg/kg), p.o. daily
IX	Doxorubicin (5 mg/kg), i.p. on 1 <sup>st</sup> , 8 <sup>th</sup> and 15 <sup>th</sup> days +D-Pinitol (300 mg/kg), p.o. daily
X	Doxorubicin (5 mg/kg), i.p. on 1 <sup>st</sup> , 8 <sup>th</sup> and 15 <sup>th</sup> days +D-Pinitol (400 mg/kg), p.o. daily

Selection of doses of Doxorubicin and D-Pinitol were based on Hajra *et al.*, and Navarro *et al.*, respectively.

The analyzer was set ready for analysis of the blood. Pre-dilution mode was selected in the analyzer. The tube was set to the sample probe. The start button was switched on.


After the buzzer sound heard and the screen of the analyzer displayed ‘analysing’, the tube was removed from the probe. When the screen showed ‘Ready’, the next sample was prepared, and the same procedure was repeated. The samples should be run within 30 minutes of dilution; otherwise, the samples will be clumped and lead to erroneous results<sup>22</sup>.

**RESULTS AND DISCUSSION:** The effects of D-Pinitol pretreatment on the haematological parameters (white blood cells, lymphocytes, monocytes, red blood cells, hemoglobin, hematocrit and platelets) of mice after exposure to DOX were represented in the tables and figures **Table 2, 3, 4, 5, 6, 7 & 8** and **Fig. 1, 2, 3, 4, 5, 6 & 7**. All groups of animals expressed normal values for all haematological parameters on day 1 (before treatment).

**TABLE 2: PROTECTIVE EFFECT OF D-PINITOL ON WHITE BLOOD CELLS OF DIFFERENT GROUPS OF MICE EXPOSED TO DOX**

Day	White Blood Cells (10 <sup>3</sup> /μl)									
	Group I (Control-0.9% Normal saline)	Dose in mg/kg								
	Group II (DOX 5)	Group III (D-P 100)	Group IV (D-P 200)	Group V (D-P 300)	Group VI (D-P 400)	Group VII (DOX 5+ D-P 100)	Group VIII (DOX 5+ D-P 200)	Group IX (DOX 5+ D-P 300)	Group X (DOX 5+ D-P 400)	
Day 1	8.5±0.103	8.7±0.063	8.317±0.204	8.65±0.327	8.417±0.162	8.783±0.236	8.267±0.178	8.833±0.23	8.85±0.067	8.817±0.168
Day 15	9.217±0.174	2.717±0.26 <sup>a*</sup>	9.067±0.173 <sup>aNS</sup>	8.95±0.169 <sup>aNS</sup>	8.883±0.232 <sup>aNS</sup>	8.617±0.158 <sup>aNS</sup>	3.55±0.159 <sup>a*b@</sup>	5.383±0.185 <sup>a*b*</sup>	6.717±0.218 <sup>a*b*</sup>	8.133±0.105 <sup>a#b*</sup>

Abbreviation: DOX – Doxorubicin; D-P – D-Pinitol. Mean ± SEM, n=6, where, a- Group II, III, IV, V, VI, VII, VIII, IX & X compared with Group I. b- Group VII, VIII, IX & X compared with Group II. \* P < 0.001, # P < 0.01 & @ P < 0.05.



**FIG. 1: HISTOGRAM - PROTECTIVE EFFECT OF D-PINITOL ON WBC OF MICE EXPOSED TO DOX**

**TABLE 3: PROTECTIVE EFFECT OF D-PINITOL ON LYMPHOCYTES OF DIFFERENT GROUPS OF MICE EXPOSED TO DOX**

Day	Lymphocytes (10 <sup>3</sup> /μl)									
	Group I (Control-0.9% Normal saline)	Dose in mg/kg								
	Group II (DOX 5)	Group III (D-P 100)	Group IV (D-P 200)	Group V (D-P 300)	Group VI (D-P 400)	Group VII (DOX 5+ D-P 100)	Group VIII (DOX 5+ D-P 200)	Group IX (DOX 5+ D-P 300)	Group X (DOX 5+ D-P 400)	
Day 1	6.717±0.185	6.683±0.114	6.533±0.223	6.683±0.196	6.567±0.186	6.117±0.182	6.717±0.221	6.6±0.248	6.733±0.163	6.58±0.221
Day 15	5.833±0.171	1.8±0.058 <sup>a*</sup>	5.9±0.285 <sup>aNS</sup>	6.067±0.461 <sup>aNS</sup>	6.267±0.38 <sup>aNS</sup>	6.233±0.131 <sup>aNS</sup>	2.633±0.163 <sup>a*b#</sup>	3.433±0.263 <sup>a*b*</sup>	4.483±0.192 <sup>a*b*</sup>	4.933±0.184 <sup>a#b*</sup>

Abbreviation: DOX – Doxorubicin; D-P – D-Pinitol. Mean ± SEM, n=6, where, a- Group II, III, IV, V, VI, VII, VIII, IX & X compared with Group I. b- Group VII, VIII, IX & X compared with Group II. \* P < 0.001, # P < 0.01 & @ P < 0.05.




FIG. 2: HISTOGRAM-PROTECTIVE EFFECT OF D-PINITOL ON LYMPHOCYTES OF MICE EXPOSED TO DOX

TABLE 4: PROTECTIVE EFFECT OF D-PINITOL ON MONOCYTES OF DIFFERENT GROUPS OF MICE EXPOSED TO DOX

Day	Monocytes (10 <sup>3</sup> /µl)									
	Group I (Control-0.9% Normal saline)	Dose in mg/kg								
	Group II (DOX 5)	Group III (D-P 100)	Group IV (D-P 200)	Group V (D-P 300)	Group VI (D-P 400)	Group VII (DOX 5+ D-P 100)	Group VIII (DOX 5+D-P 200)	Group IX (DOX 5+ D-P 300)	Group X (DOX 5+ D-P 400)	
Day 1	0.74±0.019	0.69±0.024	0.68±0.015	0.71±0.018	0.73±0.017	0.69±0.026	0.72±0.025	0.66±0.015	0.74±0.022	0.683±0.031
Day 15	0.578±0.023	0.178±0.01 <sup>a*</sup>	0.565±0.038 <sup>aNS</sup>	0.553±0.014 <sup>aNS</sup>	0.557±0.028 <sup>aNS</sup>	0.542±0.028 <sup>aNS</sup>	0.247±0.014 <sup>a*b@</sup>	0.347±0.014 <sup>a*b*</sup>	0.433±0.014 <sup>a*b*</sup>	0.507±0.016 <sup>a@b*</sup>

Abbreviation: DOX – Doxorubicin; D-P – D-Pinitol. Mean ± SEM, n=6, where, a- Group II, III, IV, V, VI, VII, VIII, IX & X compared with Group I. b- Group VII, VIII, IX & X compared with Group II. \* P < 0.001, # P < 0.01 & @ P < 0.05.




FIG. 3: HISTOGRAM - PROTECTIVE EFFECT OF D-PINITOL ON MONOCYTES OF MICE EXPOSED TO DOX

TABLE 5: PROTECTIVE EFFECT OF D-PINITOL ON RED BLOOD CELLS OF DIFFERENT GROUPS OF MICE EXPOSED TO DOX

Day	Red Blood Cells (10 <sup>6</sup> /µl)									
	Group I (Control-0.9% Normal saline)	Dose in mg/kg								
	Group II (DOX 5)	Group III (D-P 100)	Group IV (D-P 200)	Group V (D-P 300)	Group VI (D-P 400)	Group VII (DOX 5+D-P 100)	Group VIII (DOX 5+D-P 200)	Group IX (DOX 5+ D-P 300)	Group X (DOX 5+ D-P 400)	
Day 1	7.21±0.082	7.575±0.323	7.033±0.136	7.217±0.318	7.875±0.25	7.217±0.098	7.35±0.043	7.8±0.271	7.717±0.209	7.783±0.229
Day 15	7.25±0.096	4.817±0.151 <sup>a*</sup>	7.167±0.178 <sup>aNS</sup>	7.383±0.343 <sup>aNS</sup>	7.217±0.122 <sup>aNS</sup>	7.117±0.13 <sup>aNS</sup>	5.65±0.188 <sup>a*b#</sup>	6.533±0.238 <sup>a@b*</sup>	7.017±0.178 <sup>aNSb*</sup>	7.133±0.131 <sup>aNSb*</sup>

Abbreviation: DOX – Doxorubicin; D-P – D-Pinitol. Mean ± SEM, n=6, where, a- Group II, III, IV, V, VI, VII, VIII, IX & X compared with Group I. b- Group VII, VIII, IX & X compared with Group II. \* P < 0.001, # P < 0.01 & @ P < 0.05.




FIG. 4: HISTOGRAM - PROTECTIVE EFFECT OF D-PINITOL ON RBC OF MICE EXPOSED TO DOX




FIG. 5: HISTOGRAM - PROTECTIVE EFFECT OF D-PINITOL ON HEMOGLOBIN OF MICE EXPOSED TO DOX

TABLE 6: PROTECTIVE EFFECT OF D-PINITOL ON HEMOGLOBIN OF DIFFERENT GROUPS OF MICE EXPOSED TO DOX

Day	Hemoglobin (G/Dl)									
	Group I (Control-0.9% Normal saline)	Dose in mg/kg								
	Group II (DOX 5)	Group III (D-P 100)	Group IV (D-P 200)	Group V (D-P 300)	Group VI (D-P 400)	Group VII (DOX 5+D-P 100)	Group VIII (DOX 5+D-P 200)	Group IX (DOX 5+D-P 300)	Group X (DOX 5+D-P 400)	
Day 1	12.1±0.106	12.48±0.152	11.58±0.176	12.6±0.171	12.35±0.118	12.15±0.141	12.17±0.273	13.08±0.164	13±0.086	13.12±0.146
Day 15	12.48±0.154	8.567±0.198 <sup>a*</sup>	12.23±0.115 <sup>aNS</sup>	12.68±0.178 <sup>aNS</sup>	12.6±0.106 <sup>aNS</sup>	12.08±0.122 <sup>aNS</sup>	9.4±0.186 <sup>a*b@</sup>	10.42±0.158 <sup>a*b*</sup>	11.35±0.193 <sup>a#b*</sup>	11.63±0.189 <sup>a@b*</sup>

Abbreviation: DOX – Doxorubicin; D-P – D-Pinitol. Mean ± SEM, n=6, where, a- Group II, III, IV, V, VI, VII, VIII, IX & X compared with Group I. b- Group VII, VIII, IX & X compared with Group II. \* P < 0.001, # P < 0.01 & @ P < 0.05.

TABLE 7: PROTECTIVE EFFECT OF D-PINITOL ON HEMATOCRIT (HCT) OF DIFFERENT GROUPS OF MICE EXPOSED TO DOX


Day	HCT %									
	Group I (Control-0.9% Normal saline)	Dose in mg/kg								
	Group II (DOX 5)	Group III (D-P 100)	Group IV (D-P 200)	Group V (D-P 300)	Group VI (D-P 400)	Group VII (DOX 5+D-P 100)	Group VIII (DOX 5+D-P 200)	Group IX (DOX 5+D-P 300)	Group X (DOX 5+D-P 400)	
Day 1	39.27±0.204	41.32±0.375	38.18±0.397	39.05±0.148	40.08±0.209	39.22±0.328	39.68±0.416	42.17±0.33	41.82±0.348	42.08±0.151
Day 15	45.08±0.335	26.32±0.367 <sup>a*</sup>	45.57±2.157 <sup>aNS</sup>	44.3±1.751 <sup>aNS</sup>	44.53±1.77 <sup>aNS</sup>	44.17±1.922 <sup>aNS</sup>	29.03±0.894 <sup>a*b@</sup>	33.17±0.209 <sup>a*b*</sup>	35.33±0.268 <sup>a*b*</sup>	37.4±0.258 <sup>a*b*</sup>

Abbreviation: DOX – Doxorubicin; D-P – D-Pinitol. Mean ± SEM, n=6, where, a- Group II, III, IV, V, VI, VII, VIII, IX & X compared with Group I. b- Group VII, VIII, IX & X compared with Group II. \* P < 0.001, # P < 0.01 & @ P < 0.05.


TABLE 8: PROTECTIVE EFFECT OF D-PINITOL ON PLATELETS OF DIFFERENT GROUPS OF MICE EXPOSED TO DOX

Day	Platelets (10 <sup>3</sup> /μl)									
	Group I (Control-0.9% Normal saline)	Dose in mg/kg								
	Group II (DOX 5)	Group III (D-P 100)	Group IV (D-P 200)	Group V (D-P 300)	Group VI (D-P 400)	Group VII (DOX 5+D-P 100)	Group VIII (DOX 5+D-P 200)	Group IX (DOX 5+D-P 300)	Group X (DOX 5+D-P 400)	
Day 1	506.3±7.645	499.5±6.329	485±7.933	510.5±7.961	518.2±12.72	501.5±11.25	512.2±10.53	496.5±7.36	502.3±13.65	506.7±5.358
Day 15	525.7±10.57	296.2±5.907 <sup>a*</sup>	527.7±16.04 <sup>aNS</sup>	523.8±7.139 <sup>aNS</sup>	530.2±7.812 <sup>aNS</sup>	527.2±2.762 <sup>aNS</sup>	347.2±8.412 <sup>a*b#</sup>	353.8±7.613 <sup>a*b*</sup>	370.7±9.175 <sup>a*b*</sup>	417.7±10.56 <sup>a*b*</sup>

Abbreviation: DOX – Doxorubicin; D-P – D-Pinitol. Mean ± SEM, n=6, where, a- Group II, III, IV, V, VI, VII, VIII, IX & X compared with Group I. b- Group VII, VIII, IX & X compared with Group II. \* P < 0.001, # P < 0.01 & @ P < 0.05.



**FIG. 6: HISTOGRAM - PROTECTIVE EFFECT OF D-PINITOL ON HEMATOCRIT OF MICE EXPOSED TO DOX**



**FIG. 7: HISTOGRAM - PROTECTIVE EFFECT OF D-PINITOL ON PLATELETS OF MICE EXPOSED TO DOX**

Our findings showed that after 15 days of treatment, D-Pinitol had no marked effects on haematological parameters in the D-Pinitol-only treated groups compared to the control group. DOX (5 mg/kg) significantly ( $p < 0.001$ ) reduced the levels of the haematological parameters (white blood cells, lymphocytes, monocytes, red blood cells, hemoglobin, hematocrit and platelets) compared to the control animals. However, in the DOX and D-Pinitol co-treated groups, D-Pinitol (100 mg/kg, 200 mg/kg, 300 mg/kg and 400 mg/kg) restored the blood levels of haematological parameters to a greater degree in a dose-dependent manner ( $P < 0.001$ , compared with DOX group). Hence our results confirmed that DOX treatment caused an abnormal decrease in the blood levels of haematological parameters, but pretreatment of D-Pinitol with DOX resulted in a restoration of those levels to normal. In prior findings, it was concluded that DOX administration has resulted in recurrent and severe cardio toxicity and bone marrow suppression<sup>1,2</sup>.

Peripheral Cytopenia resulting from hematopoietic suppression is recurrent dose-limiting side effect of DOX. DOX-induced cytotoxicity in bone marrow cells inhibits the function of proliferating hematopoietic precursor cells, leading to deprivation of formed elements. These toxicities of DOX contribute to decreased patient's quality of life<sup>23</sup>. It is generally recognized that oxidative stress and the production of free radicals may serve as an essential role in the mechanism of DOX-induced cytotoxicity in bone marrow cells<sup>1,4</sup>. As a result, a non-toxic 'regimen' having an antioxidant

effect and free radical scavenging activity with improving the effectiveness of DOX without increasing its toxic effect is expected to enhance the treatment of cancer patients<sup>15, 16</sup>. Haematological parameters were analysed in an Automated Hematology Analyzer using peripheral blood of mice to know the ability of D-Pinitol in the prevention of DOX-induced cytotoxicity in bone marrow cells. Our studies have confirmed the protective effect of D-Pinitol against DOX-induced cytotoxicity in bone marrow cells by restoring the abnormal blood levels of haematological parameters due to DOX to the normal levels. It could be correlated mainly with the role of D-Pinitol as a free radical scavenger and an antioxidant<sup>13, 14</sup>. The data revealed that the use of D-Pinitol with DOX could strengthen the therapeutic effect by reducing its cytotoxicity.

**CONCLUSION:** In this study, it was observed that D-Pinitol (100 mg/kg, 200 mg/kg, 300 mg/kg, and 400 mg/kg) co-treated with DOX (5 mg/kg) restored the suppressed blood levels of white blood cells, lymphocytes, monocytes, red blood cells, hemoglobin, hematocrit and platelets due to DOX administration to normal blood levels. The protective role of D-Pinitol may be due to its antioxidant effect and free radicals scavenging activity. The co-administration of D-Pinitol with DOX has the merits of enhancing the prognosis of DOX chemotherapy.

**ACKNOWLEDGEMENT:** The authors thank the authorities of Adhiparasakthi College of Pharmacy for providing the necessary facilities.

The published work is a part of Ph.D., Thesis of The Tamilnadu Dr. M. G. R. Medical University.

**FUNDING SUPPORT:** The authors declare that they have no funding support for this study.

**CONFLICTS OF INTEREST:** The authors declare that they have no conflict of interest for this study.

## REFERENCES:

- Chen T, Shen HM, Deng ZY, Yang ZZ, Zhao RL, Wang L, Feng ZP, Liu C, Li WH and Liu ZJ: A herbal formula, SYKT, reverses doxorubicin-induced myelosuppression and cardiotoxicity by inhibiting ROS-mediated apoptosis. *Mol Med Rep* 2017; 15: 2057-66.
- Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA and Karuppusamy I: Toxicity of Doxorubicin (Dox) to different experimental organ systems. *Life Sci* 2018; 200: 26-30.
- Aamina M, Alhowail A, Aldubayan M and Rabbani SI: Ameliorative effect of *Terminalia chebula* on hematological complications induced by doxorubicin. *Biomed Pharmacol J* 2020; 13(3): 1245-49.
- Quiles JL, Huertas JR, Battino M, Mataix J and Ramírez-Tortosa MC: Antioxidant nutrients and adriamycin toxicity. *Toxicology* 2002; 180(1): 79-95.
- López-Sánchez JI, Moreno DA and García-Viguera C: D-pinitol, a highly valuable product from carob pods: Health-promoting effects and metabolic pathways of this natural super-food ingredient and its derivatives. *AIMS Agric Food* 2018; 3(1): 41-63.
- Sánchez-Hidalgo M, León-González AJ, Gálvez-Peralta M, González-Mauraza NH and Martín-Cordero C: D-Pinitol: a cyclitol with versatile biological and pharmacological activities. *Phytochem Rev* 2020; doi: 10.1007/s11101-020-09677-6.
- Wiśniewski K, Jozwik M and Wojtkiewicz J: Cancer Prevention by natural products introduced into the diet selected cyclitols. *Int J Mol Sci* 2020; 21(23): 1-21.
- Eser F, Altundag EM, Gedik G, Demirtas I, Onal A and Selvi B: Anti-inflammatory effect of D-pinitol isolated from the leaves of *Colutea cilicica* Boiss B et al. on K562 cells. *Turk J Biochem* 2017; 42(4): 1-6.
- Silva JÚnior JAD, Silva ACVFD, Figueiredo LS, Araujo TR, Freitas IN, Carneiro EM, Ribeiro ES and Ribeiro RA: D-Pinitol increases insulin secretion and regulates hepatic lipid metabolism in msg-obese mice. *An Acad Bras Cienc* 2020; 92(4): 1-14.
- Srivastava K, Tiwari M, Dubey A and Dubey A: D-Pinitol - A Natural Phytomolecule and its Pharmacological effect. *Int J Pharm Life Sci* 2020; 11(5): 6609-23.
- Vasaikar N, Mahajan U, Patil KR, Suchal K, Patil CR, Ojha S and Goyal SN: D-Pinitol attenuates cisplatin-induced nephrotoxicity in rats: Impact on Proinflammatory cytokines. *Chem Biol Interact* 2018; 290: 6-11.
- Folch J, Ettcheto M, Petrov D, Abad S, Pedrós I, Marin M, Olloquequi J and Camins A: Review of the advances in treatment for Alzheimer disease: strategies for combating  $\beta$ -amyloid protein. *Neurología* 2018; 33(1): 47-58.
- Orthen B, Popp M and Smirnov N: Hydroxyl radical scavenging properties of cyclitols. *P Roy Soc Edinb B* 1994; 102: 269-72.
- Rengarajan T, Rajendran P, Nandakumar N, Balasubramanian MP and Nishigaki I: Free radical scavenging and antioxidant activity of D-pinitol against 7, 12- Dimethylbenz(a) Anthracene induced breast cancer in Sprague Dawley rats. *Asian Pac J Trop Dis* 2014; 4(5): 384-90.
- Carrasco R, Ramirez MC, Nes K, Schuster A, Aguayo R, Morales M, Ramos C, Hasson D, Sotomayor CG, Henriquez P, Cortés I, Erazo M, Salas C and Gormaz JG: Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial). *Trials* 2020; 21(1): 1-10.
- Jabłońska-Trypuć A, Krętownski R, Kalinowska M, Świdorski G, Cechowska-Pasko M and Lewandowski W: Possible Mechanisms of the Prevention of Doxorubicin Toxicity by Cichoric Acid Antioxidant Nutrient. *Nutrients* 2018; 10: 1-21.
- Fukuda T, Asou E, Nogi K and Goto K: Evaluation of mouse red blood cell and platelet counting with an automated hematology analyser. *J Vet Med Sci* 2017; 79(10): 1707-1711.
- Committee for the Purpose of Control and Supervision on Experiments on Animals. CPCSEA Guidelines for Laboratory Animal Facility. *Indian J Pharmacol* 2003; 35(4): 257-74.
- Hajra S, Patra AR, Basu A and Bhattacharya S: Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: Effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation. *Biomed Pharmacother* 2018; 101: 228-43. doi:10.1016/j.biopha.2018.02.088.
- Navarro JA, Decara J, Medina-Vera D, Tovar R, Suarez J, Pavón J, Serrano A, Vida M, Gutierrez-Adan A, Sanjuan C, Baixeras E and Fonseca FR de: D-Pinitol from *Ceratoniasiliqua* Is an Orally Active Natural Inositol That Reduces Pancreas Insulin Secretion and Increases Circulating Ghrelin Levels in Wistar Rats. *Nutrients* 2020; 12(7): 1-22.
- Padmanabhan S, Tripathi DN, Vikram A, Ramarao P and Jena GB: Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: Intervention of folic and folinic acid. *Mutat Res* 2009; 673(1): 43-52.
- Wiedmeyer CE, Ruben D and Franklin C: Complete Blood Count, Clinical Chemistry, and Serology Profile by Using a Single Tube of Whole Blood from Mice. *J Am Assoc Lab Anim Sci* 2007; 46(2): 59-64.
- Remesh A: Toxicities of anticancer drugs and its management. *Int J Basic Clin Pharmacol* 2012; 1(1): 2-12.

### How to cite this article:

Sudha M and Vetrichelvan T: Protective effect of D-Pinitol isolated from aerial parts of Soybean plants on haematological profile against doxorubicin induced cytotoxicity in mice. *Int J Pharm Sci & Res* 2021; 12(5): 2926-32. doi: 10.13040/IJPSR.0975-8232.12(5).2926-32.